Status:
UNKNOWN
COVID-19 Vaccine Reactogenicity and Immunogenicity
Lead Sponsor:
Korea University Guro Hospital
Collaborating Sponsors:
Catholic Kwandong University
Ajou University School of Medicine
Conditions:
COVID-19
Vaccine Immune Response
Eligibility:
All Genders
19-55 years
Brief Summary
Analysis of antibody kinetics after vaccination with mRNA-1273 and factors influencing the vaccine immunogenicity
Detailed Description
We conducted a prospective study on healthy young adults who were to receive two doses of mRNA-1273 vaccine at 28-day intervals. After each dose, adverse events were prospectively evaluated, and blood...
Eligibility Criteria
Inclusion
- who were willing to receive the mRNA-1273 vaccine
Exclusion
- previously diagnosed with laboratory-confirmed COVID-19
- history of autoimmune disease
- immunocompromised, pregnant, or breastfeeding
Key Trial Info
Start Date :
June 24 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 30 2022
Estimated Enrollment :
179 Patients enrolled
Trial Details
Trial ID
NCT05258708
Start Date
June 24 2021
End Date
May 30 2022
Last Update
February 28 2022
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Catholic Kwandong University
Incheon, South Korea
2
Kangnam Sacred Heart Hospital
Seoul, South Korea
3
Korea University Anam Hospital
Seoul, South Korea
4
Korea University Guro Hospital, International St. Mary's Hospital, Gangnam Sacred Heart Hospital, Ajou University School of Medicine, Korea University Anam Hospital
Seoul, South Korea